Hepatocyte Growth Factor/C-Met Axis in Thyroid Cancer: From Diagnostic Biomarker to Therapeutic Target

Biomarker Insights - New Zealand
doi 10.1177/1177271917701126
Full Text
Abstract

Available in full text

Date
Authors
Publisher

SAGE Publications

Related search

C-Met as a Potential Therapeutic Target and Biomarker in Cancer

Therapeutic Advances in Medical Oncology
Oncology
2011English

PET of C-Met in Cancer With 64Cu-Labeled Hepatocyte Growth Factor

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2015English

C-Met Proto-Oncogene (MET; HGFR); Hepatocyte Growth Factor/Scatter Factor (HGF/SF)

Science-Business eXchange
2014English

Hepatocyte Growth Factor/C-Met Signaling in Head and Neck Cancer and Implications for Treatment

Cancers
Cancer ResearchOncology
2017English

The PREX1/Rac Signaling Axis: Potential as a Biomarker and Therapeutic Target in Breast Cancer

Molecular and Cellular Oncology
Cancer ResearchMolecular Medicine
2015English

MAP Kinase Kinase Kinase 8 (MAP3K8; COT; TPL2); C-Met Proto-Oncogene (MET; HGFR); Hepatocyte Growth Factor/Scatter Factor (HGF/SF)

Science-Business eXchange
2012English

Growth Differentiating Factor-15 (GDF-15): A Potential Biomarker and Therapeutic Target for Cancer-Associated Weight Loss

Oncology Letters
Cancer ResearchOncology
2016English

C-Met: A Potential Therapeutic Target for Hepatocellular Carcinoma

Drug discoveries & therapeutics
MedicineToxicologyPharmaceuticsPharmacology
2011English

Down-Regulation of MET, the Receptor for Hepatocyte Growth Factor

Oncogene
Cancer ResearchGeneticsMolecular Biology
2001English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy